National and Kapodistrian University of Athens
Progression of subclinical atherosclerosis and central hemodynamics in patients with antiphospholipid syndrome
Abstract
dc:descriptionBackground/Aims: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with antiphospholipid syndrome (APS). Atherosclerosis plays the central role in CVD pathophysiology and increased arterial stiffness (ArS) further deteriorates vascular health. Increased prevalence of subclinical atherosclerosis has been described in patients with APS, but the progression of this phenomenon had not been studied before. Although ArS has emerged as an independent prognostic factor for future CVD events, limited data were available for ArS characteristics in the APS population. In this dissertation, we aimed to examine ArS and progression of subclinical atherosclerosis in APS patients. We compared the results of APS patients with those derived from healthy controls (HC), but also from patients with diabetes mellitus (DM), a disease with well-established high CVD risk. We also sought for factors that influence subclinical atherosclerosis process and ArS in APS. Methods: Patients with thrombotic APS, fulfilling the revised Sapporo criteria for definite APS, that are followed-up in the Rheumatology Unit of the First Department of Propaedeutic Internal Medicine (Medical School, National and Kapodistrian University of Athens, Greece) were considered for eligibility. Patients with both primary APS (PAPS) and patients with concomitant systemic lupus erythematosus (SLE, SLE-APS) were recruited. APS patients with known history of atherosclerotic CVD, isolated obstetric APS, concomitant DM, history of other autoimmune disorder, chronic kidney disease (CKD) of stage V, pregnancy, active infection or malignancy were excluded. APS individuals were matched 1:1:1 for age and sex with patients with DM, followed-up in the Diabetes Center of the same Department, and healthy subjects. From 2012 to 2016, 86 APS patients and same number of age- and sex-matched DM patients and HC underwent a baseline ultrasound of carotid and femoral arteries to examine for atherosclerotic plaques presence. We prospectively invited all participants after 3 and 7 years for a follow-up ultrasound evaluation to record the development of new atherosclerotic plaques.From 2012 to 2022, we cross-sectionally enrolled 110 APS patients and equal number of age- and sex-matched DM patients and healthy individuals to investigate ArS, by measuring carotid-femoral pulse wave velocity (cfPWV) and augmentation index (AIx) corrected to 75 beats per minute (AIx@75), using the Sphygmocor device. In the same visit, ultrasound of carotid and femoral arteries was also conducted in order to detect possible subclinical atherosclerosis. In all visits, demographic, clinical and laboratory data were recorded. Multivariate regression analyses were performed to compare atherosclerotic plaque progression and ArS markers between APS, DM and HC groups, after adjusting for several possible confounding factors. Within the group of APS patients, we also sought for parameters that are associated with enhanced atherosclerosis progression or increased ArS, by applying multivariate regression models. Results: A total of 205 participants were included in the 3-year follow-up atherosclerosis progression study: 74 APS patients (38 with PAPS, 36 with SLE-APS), 58 DM patients and 73 HC. At the follow-up visit, new atherosclerotic plaques were observed in 25.7% of APS patients, 24.1% of DM patients and 11% of HC. After adjusting for traditional CVD risk factors (CVRFs) and baseline plaque presence, patients with APS demonstrated a 3.3-fold increased risk for atherosclerosis progression compared to healthy subjects (OR=3.30 [1.12-9.75], p=0.031), which was similar to that observed in DM patients (OR=3.45 [1.14-10.39], p=0.028). In patients with APS, risk for new plaque development was higher in SLE-APS patients versus those with PAPS (OR=7.75, p=0.038) and was independently associated with traditional CVRFs presence (OR=2.31, p=0.008), as expressed by the Systematic COronary Risk Evaluation score (SCORE). Sixty-four APS patients (75% females, 43.8% with primary APS), 58 DM patients and 66 healthy individuals were re-evaluated in the 7-year ultrasound visit. Compared to the baseline examination, new atherosclerotic plaque was detected in 51.6%, 36.2% and 25.8% of APS, DM and HC, respectively. After adjusting for the number of traditional CVRFs and for the presence of subclinical atherosclerosis at baseline, APS patients showed a 3-fold (OR=3.07, p=0.007) higher risk for atherosclerosis progression compared to HC and 2-fold (OR=2.25, p=0.047) higher risk than patients with DM. In multivariate analysis within the APS population, new plaque formation was independently associated with concomitant SLE diagnosis (OR=7.78, p=0.005) and the number of prevalent CVRFs at baseline (OR=3.02, p=0.002). Sustained attainment of low-density lipoprotein (LDL) target independently reduced the risk of plaque progression during the 7-year follow-up (OR=0.34, p=0.021). We examined ArS in 110 patients with APS (70.9% female, mean age 45.4 years), 110 DM patients and 110 HC. After adjusting for age, sex, CVRFs and atherosclerotic plaque presence, APS patients showed similar cfPWV (beta=-0.142, 95% CI: -0.514, 0.230, p=0.454) but increased AIx@75 (beta=4.525, 95% CI: 1.372, 7.677, p=0.005) compared to healthy subjects, while they exhibited lower cfPWV (beta=-0.863, 95% CI: -1.223, -0.500, p<0.001) but similar AIx@75 (beta=2.046, 95% CI: -1.040, 5.132, p=0.193) to patients with DM. In multivariate analysis in the APS population, cfPWV was independently associated with age (beta=0.056, 0.034-0.078, p<0.001), mean arterial pressure (MAP) (beta=0.070, 0.043-0.097, p<0.001), atherosclerotic plaques in femoral arteries (beta=0.732, 0.053-1.411, p=0.035) and positivity for anti-β2GPI IgM (beta=0.696, 0.201-1.191, p=0.006). AIx@75 was independently related with age (beta=0.334, 0.117-0.551, p=0.003), female sex (beta=7.447, 2.312-12.581, p=0.005) and MAP (beta=0.425, 0.187-0.663, p=0.001). Conclusions: Patients with APS exhibit enhanced subclinical atherosclerosis progression and increased ArS compared to healthy individuals, in a degree comparable or even greater than DM patients. APS is a disorder with per se increased CVD burden and APS patients, especially those with concomitant SLE and prevalent traditional CVRFs, could be considered as of high CVD risk, like patients with DM. Τhe implementation of vascular ultrasound and ArS measurement in clinical practice will probably help to recognize APS patients with masked high CVD risk, who would benefit from prompt therapeutic intervention. Efficient LDL target attainment successfully decelerates new atherosclerotic plaque formation in APS patients. Regular screening of traditional CVRFs and strict CVRFs management strategies are eminent for effective CVD prevention in the high-risk population of APS patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Evangelatos, Gerasimos
- Ευαγγελάτος, Γεράσιμος
Subjects
dc:subject × 15- Αντιφωσφολιπιδικό σύνδρομο
- Αθηροσκλήρυνση
- Αρτηριακή σκληρία
- Αθηρωμάτωση
- Συστηματικός ερυθηματώδης λύκος
- Antiphospholipid syndrome
- Atherosclerosis
- Arterial stiffness
- Systemic lupus erythematosus
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ρευματολογία
- Clinical Medicine
- Medical and Health Sciences
- Rheumatology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60244